Bioniche Life Sciences Inc (BNC)

Shares / Stock Code

BNC

Stock Exchange / Sharemarket

ax

Bioniche Life Sciences Inc (BNC) is a biopharmaceutical company. The Company develops, manufactures and markets products for human and animal health markets worldwide. It operates in three segments: human health, animal health and food safety. BNC was listed on the Australian stockmarket (ASX) on 27 January, 2011.

Human Health

Its human health business unit develops human cancer therapies, with a focus on the research and development of the Company's Mycobacterial Cell Wall-DNA Complex (MCC) technology platform for the treatment of bladder and other cancers, and its oligonucleotides, which show pre-clinical promise in the treatment of leukemia and other cancers.

Bioniche has developed a technology for the treatment of human cancers. The first product developed from this technology is Urocidin™, a formulation of Mycobacterial Cell Wall-DNA Complex (MCC) for the treatment of bladder cancer. A Phase III clinical program is underway, in partnership with Endo Pharmaceuticals Inc.

Animal health

Its animal health business unit develops, manufactures and markets animal health biopharmaceutical products worldwide. Bioniche Animal Health was formed in 1979 as a privately owned company to develop vaccines and other pharmaceutical-based products for the preventative health management of animal diseases. Now a Division of the Bioniche Life Sciences Inc., a public company (TSX: BNC), Bioniche Animal Health has marketing subsidiaries in Australia, Canada, Europe, and the United States.

It is responsible for research, development, manufacturing, and marketing of veterinary biopharmaceutical products worldwide. The Division has a portfolio of products centered around five platform technologies in the broad categories of reproduction and embryo transfer; immunostimulants; and vaccines. Close liaisons have been established with a number of universities active in medical and veterinary research. These liaisons support and strengthen the research and development program, which is primarily focused on reducing the reliance on antibiotics in animal health care and on enhancing reproductive performance in animals.

Bioniche Life Sciences: Food safety

Its food safety business unit is engaged in researching, developing, manufacturing and marketing of veterinary biopharmaceutical products. In July 2009, it had signed a licensing, development and supply agreement UrocidinTM, a formulation of MCC for the treatment of bladder cancer.

Econiche is a vaccine for healthy cattle used as an aid in the reduction of shedding Escherichia coli (E. coli) O157. This new innovation – the world's first licensed on-farm vaccine against E. coli O157 – is expected to be a useful tool in reducing the risk to public health.